GalenicaXSWX:GALE -0.23%81 Return-on-Tangible-Asset is 9.74% as of Dec. 2025, which is 7% below its 10-year median of 10.49. GuruFocus rates XSWX:GALE with a GF Score™ of 81/100 and a GF Value™ of CHF86.08 (Fairly Valued). The stock has 1 warning sign investors should review. Among 118 Medical Distribution companies, Galenica ranks better than 88.98% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Galenica's annualizedNet Income for the quarter that ended in Dec. 2025 was CHF186 Mil. Galenica's average total tangible assets for the quarter that ended in Dec. 2025 was CHF1,905 Mil. Therefore, Galenica's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 9.74%.
The historical rank and industry rank for Galenica's Return-on-Tangible-Asset or its related term are showing as below:
XSWX:GALE'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 6.8 Med: 10.49 Max: 16.66
Current: 9.42
During the past 13 years, Galenica's highest Return-on-Tangible-Asset was 16.66%. The lowest was 6.80%. And the median was 10.49%.
XSWX:GALE's Return-on-Tangible-Asset is ranked better than 88.98% of 118
companies
in the Medical Distribution industry
Industry Median: 2.305
vs XSWX:GALE: 9.42
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Galenica Return-on-Tangible-Asset Related Terms
Galenica Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Galenica's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALE vs MCK, CAH, COR: Return-on-Tangible-Asset Comparison
For the Medical Distribution subindustry, Galenica's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galenica Return-on-Tangible-Asset vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Galenica's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Galenica's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 9.74% mean?
Galenica (XSWX:GALE) has a Return-on-Tangible-Asset of 9.74% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Galenica and its competitors. This is near median its historical median of 10.49. Over the past decade, Galenica's Return-on-Tangible-Asset has ranged from 6.80 to 16.66. According to the industry distribution chart, Galenica ranks #13 out of 118 companies in the Medical Distribution industry, placing it in the top 11%.
Is Galenica's Return-on-Tangible-Asset too high?
Galenica's current Return-on-Tangible-Asset of 9.74% is near median its 10-year median of 10.49. Over the past 10 years, this metric has ranged from a low of 6.80 to a high of 16.66. The Medical Distribution industry median Return-on-Tangible-Asset is 2.31. Galenica's value of 9.74% is 322.6% above this industry median. Based on the distribution chart, Galenica ranks #13 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Galenica has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Galenica's Return-on-Tangible-Asset compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Galenica ranks #13 out of 118 companies for Return-on-Tangible-Asset. This places Galenica in the top 11% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 2.31. Galenica's value of 9.74% is 322.6% above this benchmark. Historically, Galenica's own Return-on-Tangible-Asset has ranged from 6.80 to 16.66 over the past decade. While the company's 10-year median is 10.49 vs. the industry median of 2.31, Galenica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Distribution company?
The median Return-on-Tangible-Asset among Medical Distribution companies is 2.31, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galenica's current Return-on-Tangible-Asset of 9.74% is 322.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Galenica and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Asset is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galenica's current Return-on-Tangible-Asset is 9.74%, which is near median its own 10-year median of 10.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galenica stock overvalued right now?
Based on GuruFocus' analysis, Galenica (XSWX:GALE) is currently considered Fairly Valued. The stock's GF Value™ is CHF86.08, compared to a current price of CHF86.75 — trading 0.8% above its estimated fair value. The current Return-on-Tangible-Asset is 9.74%, which is near median its 10-year median of 10.49 and 322.6% above the Medical Distribution industry median of 2.31. Galenica's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Galenica (XSWX:GALE), the current Return-on-Tangible-Asset is 9.74% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Galenica (XSWX:GALE) Overvalued in 2026?
Based on GuruFocus' analysis, Galenica stock appears to be overvalued.
The current stock price of CHF86.75 is trading 0.8% above its estimated GF Value™ of CHF86.08.
GuruFocus considers Galenica to be Fairly Valued.
Key valuation signals for XSWX:GALE:
Return-on-Tangible-Asset: 9.74% (near median its 10-year median of 10.49)
GF Value™: CHF86.08 vs. price of CHF86.75 (0.8% above fair value)
Industry Position: 322.6% above the Medical Distribution median (#13 of 118)
No single metric tells the full story. See the XSWX:GALE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Galenica Ltd is an integrated healthcare service provider in Switzerland. The business is operated from two segments Products & Care and Logistics & IT. The Products & Care segment comprises the Retail business area with offerings for patients and end customers and the Professionals business area with offerings for business customers and partners in the healthcare sector. The Logistics & IT segment comprises the two sectors Wholesale and Logistics & IT Services. These provide services for all those involved in the healthcare sector - pharmacies, drugstores, doctors, hospitals and care homes, partners, and suppliers. Geographically, it operates in Switzerland and Other Countries.
81GF Score
Get the complete analysis for XSWX:GALE
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALE has been successfully added to your 
